Modern Risk Stratification of Acute Myeloid Leukemia in 2023: Integrating Established and Emerging Prognostic FactorsEleonora Boscaro, Marco Cerrano, Stefano D’Ardìa et al.|Cancers|2023Cited by 35
Sorafenib in combination with intensive chemotherapy for relapsed or refractory FLT3-ITD positive acute myeloid leukemia: A two centers experienceIrene Urbino, Marco Cerrano, Carolina Secreto et al.|Leukemia Research|2023Cited by 2
Arsenic trioxide neurotoxicity in acute promyelocytic leukemia patients: a single center experienceGiulia Arrigo, Chiara Frairia, Matilde Scaldaferri et al.|Leukemia & lymphoma/Leukemia and lymphoma|2024Cited by 2